🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

55 results for “SUPERNUS” Clear

  1. Brexanolone

    SUPERNUS PHARMACEUTICALS, INC.

    Post Partum Depression

    phase 3 small molecule completed

    1 trial

  2. MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule completed

    2 trials

  3. MYOBLOC Low Dose

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule terminated

    1 trial

  4. Oxcarbazepine XR

    SUPERNUS PHARMACEUTICALS, INC.

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial

  5. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial

  6. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial

  7. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  8. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 small molecule completed

    2 trials

  9. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  10. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    ADHD

    phase 3 small molecule completed

    5 trials

  11. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Super-refractory Status Epilepticus

    phase 3 small molecule completed

    2 trials

  12. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

  13. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  14. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  15. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  16. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  17. BIS-001ER

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Impaired Awareness Seizures

    phase 2 small molecule active

    1 trial

  18. Botulinum Toxin Type B (Myobloc)

    SUPERNUS PHARMACEUTICALS, INC.

    Drooling

    phase 2 mab completed

    1 trial

  19. Brexanolone

    SUPERNUS PHARMACEUTICALS, INC.

    Tinnitus

    phase 2 small molecule completed

    1 trial

  20. Gocovri (extended-release amantidine)

    SUPERNUS PHARMACEUTICALS, INC.

    Radiation Encephalopathy

    phase 2 small molecule active

    1 trial

  21. Huperzine A, Huperzine A, Capsules, Huperzine A

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    1 trial

  22. IR Viloxazine

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial

  23. IR-TPM (Topamax)

    SUPERNUS PHARMACEUTICALS, INC.

    Migraine

    phase 2 small molecule terminated

    1 trial

  24. Molindone

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD in Children

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources